At present, a number of anti-tumor drugs targeting MDM2 have been developed (Konopleva et al. 2020), including APG-115 (Fang et al. 2019), KRT-232 (Zhang et al. 2020), and ALRN-6924 (Pairawan et al. 2021). This evidence concerns the gene MDM2 and neoplasm.